Victory 15 – C
Vancouver – C
Edmonton 12 – C
Regina 18 C
Winnipeg 20 – C
Toronto 27 – C
Ottawa 27oC
Montreal 30 C
Quebec 24 C
Fredericton 27 – C
Halifax 21oC
Charlottetown 26oC
San Juan 24 C
Whitehorse – C
Yellowknife ° C
Iqaluit 15oC
Health Canada has granted you conditional permission to use remdesivir for the remedy of patients with severe COVID-19 symptoms suffering from pneumonia and require more oxygen to help them breathe.
Remdesivir, the logo called Veklury, is the first drug Health Canada has legal for coVID-19 remedy, the signing announced in a press release Tuesday.
Remdesivir has received emergency or conditional authorization in the United States, Europe, Japan, Singapore and Australia. In Canada, the authorization included a full six-week clinical review.
The drug, manufactured through Gilead Sciences Canada, Inc., is licensed in adults and adolescents weighing at least 40 kg.
Gilead Sciences Canada, Inc. requested authorization for an indication of the use of remedivir to treat young people or pregnant women, Health Canada said.
Reemployment is administered intravenously and will be used in fitness facilities where patients can be largely monitored, the federal firm said.
Upon conditional authorization, Gilead Sciences Canada, Inc. will send drug protection follow-up reports to Health Canada, adding reports on all serious adverse drug reactions.
“Health Canada will continue to monitor vigorously the protection of the re-disciplinary formula in Canada and will take action in the event of a protection issue,” the firm said in a statement.
To date, a small number of patients have been treated for reemployment in Canada under the Special Access Program, Health Canada said.
With the repurposer’s permission, the special program will no longer be mandatory for the drug, the signature said.
Health Canada has two legal clinical trials to evaluate the protection and efficacy of the reuser, which will continue to gather more knowledge about the drug despite conditional approval.
“The Canadian Public Health Agency continues to lead the work with Gilead Sciences Canada, Inc. to ensure remedivir for Canadians,” Health Canada officials said.
According to the Guardian, the United States has bought “virtually all shares for the next 3 months.”
Trump’s management has more than 500,000 fixes of repobreza, all Gilead production by July and 90% in August and September, the Guardian reported on June 30.
Category
All rights reserved – Radio Canada International 2018